Ruxolitinib (Standard)

Ruxolitinib (Standard) is the analytical standard of Ruxolitinib. This product is intended for research and analytical applications. Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].

Product Specifications

CAS Number

[941678-49-5]

Product Name Alternative

INCB18424 (Standard)

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; Autophagy; JAK; Mitophagy; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ruxolitinib-standard.html

Purity

99.74

Smiles

N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2

Molecular Formula

C17H18N6

Molecular Weight

306.37

Precautions

H302

References & Citations

[1]Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115 (15), 3109-3117.|[2]Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366 (9), 799-807.|[3]Tavallai M, et al. Rationally Repurposing Ruxolitinib (Jakafi (®) ) as a Solid Tumor Therapeutic.Front Oncol. 2016 Jun 13;6:142.